rufusthrat

rufusthrat
Send Message
View as an RSS Feed
  • What Does Shkreli's Arrest Mean For KaloBios' Share Price?  [View article]
    Shkreli was asking for it, if not begging for it. Will all the notoriety he was generating a reasonable person would have laid low. In his case his mania was boundless, he kept going from strength to strength making him uncontested greediest man in America. He surely had it coming, thumbing his nose at his critics and the people of this country, he was basically daring law enforcement to try to catch him. I don't think he will be feeling invulnerable any more after this.
    Dec 17, 2015. 10:40 AM | 10 Likes Like |Link to Comment
  • MEI Pharma: ASH Abstract Data Supports Advancement Of Pracinostat In MDS And AML  [View article]
    So no run up to ASH, unless you call that uppers $1.80's a run up and now slowly selling off. Zero interest in the stock from investors so far. In March in expectation of good interim phase 3 MDS data the stock ran up to $6.50 before release of data, now even when the MDS data seems to have turned positive the stock is stuck in quicksand. Awful announcement in March 2015 and little forward direction on pracinostat by management so far has not helped either. Hopefully something will change with the upcoming ASH this week end and 1Q 2016, but longs stuck with this stock can only just hope that one of the worst biotechs of 2015 will turn around.
    Dec 2, 2015. 04:26 PM | 1 Like Like |Link to Comment
  • MEI Pharma: ASH Abstract Data Supports Advancement Of Pracinostat In MDS And AML  [View article]
    Meip has enough money for now it is expected to fund them through 2016. They will need to raise money eventually but there is no dire now. Hopefully the stock price will appreciate and be over $5 when they dilute next. What is perplexing is the lack of interest in the stock. Despite all the positive data coming out, the stock is stuck in the mud with brief multiple run ups to around $2 and dumped time and time again. Hopefully this final time before ASH will be a lasting run, but who knows ?
    Nov 11, 2015. 09:48 AM | 1 Like Like |Link to Comment
  • MEI Pharma Should Be Bought Ahead Of ASH Conference  [View article]
    The average survival for blasts > 30% is about 10 months. Average blasts in Pracinostat AML study was 40%, one year survival is estimated at 60% in the entire cohort significantly better than azacitidine alone . "The marrow blast counts ranged from 20% to 89% with a median of 40%. Thirty-one patients (62%) continue to be followed for survival (range: 8.5 to 18.5 months). Median overall survival has not been reached in the overall study population and neither in patients with high-risk cytogenics or those with AML secondary to MDS or prior anti-cancer therapy. The 1-year overall survival estimate is 60%. The primary endpoint of CR +CRi +MLFS has been observed in 27/50 evaluable patients (54%) to date, including 21/50 (42%) CR. The 60-day all-cause mortality rate is 10% (5/50)."

    This goes to show that benefit is in all high risk as well as low risk groups
    Nov 6, 2015. 05:54 PM | 1 Like Like |Link to Comment
  • MEI Pharma Should Be Bought Ahead Of ASH Conference  [View article]
    Meip is a highly manipulated stock, is slammed down every time despite good news. Yesterday's action is a perfect example, the data was good, better than expected, but same take down every time it goes above $2. It does not take too many shares in pre-market to depress the stock as happened yesterday when it quickly went down from $2.25 premarket to $1.70 . Unless large institutional holders come it, I have a difficult time seeing this change. While the buyers interest is uncertain, with the data they have so far, phase 3 with Pracinostat is almost a certainty. The best buyers can do is to have patience, if data continues to be good, MM and hedge funds are not going to be able to hold it down for ever
    Nov 6, 2015. 10:32 AM | 1 Like Like |Link to Comment
  • Enteromedics Can Tap Cash With Convertible Notes With Big Condition  [View article]
    Endless shareholder pain unfortunately with this stock
    Nov 5, 2015. 02:15 PM | Likes Like |Link to Comment
  • MEI Pharma Should Be Bought Ahead Of ASH Conference  [View article]
    Every time MEIP has tried to break north of $2 since March 2015, it has been beaten down What remains to be seen if it can clear the low $2's. We will know more tomorrow when abstracts are released, they are expected to be good.
    Nov 4, 2015. 10:16 AM | 3 Likes Like |Link to Comment
  • MEI Pharma Should Be Trading At $4 Per Share Today  [View article]
    No change from what was reported in the prior conf. The upcoming conference in next 2 weeks should have major updates, then ASH abstracts on line Nov 5
    Oct 4, 2015. 10:23 AM | Likes Like |Link to Comment
  • Orexigen Up On Dilution - Huh?  [View article]
    The reason for spike is that we are finally going to get a European launch, where Mysimba is the sole prescription weight loss drug. As there is no competition and Orex should keep 100% of the profits in Europe, European launch could be 5-10 times more profitable than US sales.
    Sep 10, 2015. 09:26 PM | 2 Likes Like |Link to Comment
  • MEI Pharma Fire Sale: A Strong Buy On Upcoming Catalysts And Undervalued Pipeline  [View article]
    Geron drug imetelstat is primarily for for Myeloproliferative disiorder (which is different from MDS) is is in phase 2 which began in 2015. Their AML/MDS data is preliminary, phase 2 has not even been started. Dvax, Agios to the best of my knowledge does not have any drugs in pipe line for AML or MDS. With sunesis pharma flopping, Meip has the lead for AML and possibly MDS
    Aug 31, 2015. 10:43 AM | 1 Like Like |Link to Comment
  • Vital Therapies -73% after failure of liver-treatment trial  [View news story]
    I am no fan of Martin Shkreli but he far from stupid as he has demonstrated by successfully shorting biotechs time and time again
    Aug 31, 2015. 02:15 AM | Likes Like |Link to Comment
  • MEI Pharma Should Be Trading At $4 Per Share Today  [View article]
    mdwork, the insiders recently got options at $1.58, so there is no reason for them to buy. The wait for AML P3 is to allow for full AML and MDS data to mature, as mentioned in this article it will allow them to determine optimal dosage of the combination (Pracinostat + Vidaza). If approved for AML, physicians can use it off label for MDS too, the data of which is looking good.
    Aug 19, 2015. 10:55 AM | 2 Likes Like |Link to Comment
  • MEI Pharma: A Rare Hidden Gem With Impressive Clinical Data  [View article]
    Timothy, Please post the link. Nothing in news that I could google. Bofa target was $9 in Feb, have they reiterated that target this week ?

    Nice Article
    http://bit.ly/1J0zzAi
    Aug 18, 2015. 12:43 PM | Likes Like |Link to Comment
  • MEI Pharma Fire Sale: A Strong Buy On Upcoming Catalysts And Undervalued Pipeline  [View article]
    If MEIP advances Pracinostat to P3 and can get approval for AML, it could be very well be used off label for MDS (esp refractory MDS) with the responses they are getting, that should give the company another boost
    Aug 15, 2015. 03:16 PM | Likes Like |Link to Comment
  • MEI Pharma Fire Sale: A Strong Buy On Upcoming Catalysts And Undervalued Pipeline  [View article]
    The conference was very encouraging. AML data continues to impress. MDS data is now turning positive too with almost almost double relapse free survival so far. The stock should run up to ASH meeting Dec 5-8, expect meip to be in $3-$4 range at least by then. ASH massive for meip with ME 344 and PWT 143 data also being reported.

    http://yhoo.it/1NrH9Fk
    Aug 12, 2015. 09:05 PM | 1 Like Like |Link to Comment
COMMENTS STATS
166 Comments
218 Likes